Investor Chione Ltd
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Chione Ltd . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-02-14 13D/A SERA / Sera Prognostics, Inc. 1,980,350 2,605,351
2024-07-10 13G/A ACRV / Acrivon Therapeutics, Inc. 3,856,597 3,848,632
2024-07-10 13G/A ACRV / Acrivon Therapeutics, Inc. 3,856,597 3,848,632
2023-02-14 13G/A KPTI / Karyopharm Therapeutics Inc. 5,000,000 4,400,000
2022-11-28 13G ACRV / Acrivon Therapeutics, Inc. 3,856,597
2022-02-11 13G/A KPTI / Karyopharm Therapeutics Inc. 5,500,000 5,000,000
2021-07-26 13D SERA / Sera Prognostics, Inc. 1,980,350
2021-02-16 13G/A KPTI / Karyopharm Therapeutics Inc. 5,695,499 5,500,000
2020-02-14 13G/A KPTI / Karyopharm Therapeutics Inc. 7,631,267 5,695,499
2019-02-13 13G/A KPTI / Karyopharm Therapeutics Inc. 8,549,920 7,631,267
2018-02-14 13G/A KPTI / Karyopharm Therapeutics Inc. 8,549,920 8,549,920
2017-02-13 13G/A KPTI / Karyopharm Therapeutics Inc. 9,000 8,549,920
2016-03-09 13G/A KPTI / Karyopharm Therapeutics Inc. 9,000
2014-02-18 13G KPTI / Karyopharm Therapeutics Inc. 10,258,079